KalVista Pharmaceuticals (NASDAQ:KALV) is being acquired by Chiesi Group for approximately $1.9 billion, a strategic move to expand Chiesi's rare disease treatment portfolio. The acquisition offer of $27.00 per share in cash led to a significant 38.62% stock price surge and massive trading volume, reflecting strong investor confidence in the deal's completion. Leerink Partners downgraded KalVista Pharmaceuticals' stock to Market Perform with a $27.00 price target, indicating that the stock's value is now p ...